Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

New Method for Identifying Kinase Inhibitors for Cancer Therapy

The most difficult subtype of breast cancer to treat is triple-negative breast cancer (TNBC). Over 20,000 cases of TNBC are reported each year in the United States alone.

10 Oct 2024

RYBREVANT Receives EC Nod for Advanced Lung Cancer Treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Type II extension of indication for RYBREVANT®▼ (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R substitution (L858R) mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

30 Aug 2024

3D Cell Cultures Improve Drug Screening Accuracy but Show Lower Efficacy for Anti-Cancer Drugs

The existing knowledge on monolayers and spheroid-based cell cultures, including the constituent compounds, and the difference in efficacy during drug screening, especially for anti-cancer drugs targeting cytoskeletal dynamics and cell cycles.

21 Jun 2024

Study explains why cancers stop responding to kinase inhibitors and come back stronger

More than 70 FDA-approved cancer drugs are kinase inhibitors, which work by blocking kinases-;enzymes that add phosphate groups to molecules in the cell-;and preventing the chemical activity necessary for signaling and growth in cancer cells.

14 Feb 2023

Researchers discover effective therapy for pediatric T-acute leukemia

The most frequent type of malignancy in kids is acute lymphoblastic leukemia (ALL).

27 Jun 2022

Rewiring the inner workings of leukemia cells to reverse drug resistance

Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukemia cells.

20 Apr 2022

ATM kinase inhibitor combines with target therapies to wipe out cancer cells

While cancer therapies that target specific genes or disease pathways might prolong life span, they can also result in highly resistant tumors when tiny reservoirs of cancer cells survive therapy, develop, and spread.

1 Apr 2022

Research uncovers key component of cellular malfunction that contributes to tumor growth

Scientists have homed in on a crucial step within the sequence of chemical reactions that govern regulation of cell division, proliferation and death, and whose malfunction contributes to the growth of tumors.

3 Nov 2021

Targeted drug shows promise against brain metastases from kidney cancer

A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.

22 Oct 2021

Researchers discover a new, effective way to treat aggressive blood cancer in children

Australian scientists have found what could prove to be a new and effective way to treat a particularly aggressive blood cancer in children.

31 May 2021

Light-controlled on/off switch can help reset the biological clock

The biological clock is present in almost all cells of an organism. As more and more evidence emerges that clocks in certain organs could be out of sync, there is a need to investigate and reset these clocks locally.

26 May 2021

New tool can provide non-invasive decision support for treating lung cancer

Personalized treatment options for patients with lung cancer have come a long way in the past two decades. For patients with non-small cell lung cancer, the most common subtype of lung cancer and the leading cause of cancer-related death worldwide, two major treatment strategies have emerged: tyrosine kinase inhibitors and immune checkpoint inhibitors.

19 Oct 2020

Researchers reveal mechanism behind osimertinib resistance in some lung-cancer patients

Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.

7 Oct 2020

Combination treatment improves outcomes in advanced kidney cancer patients

An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.

24 Sep 2020

Study indicates a powerful treatment for pulmonary fibrosis

A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the lungs of people with idiopathic pulmonary fibrosis (IPF).

7 Aug 2020